Concordance of the toxicity of pharmaceuticals in humans and in animals.
By H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, James Sanders, Glenn Sipes, W. Bracken and 5 more. Regulatory toxicology and pharmacology : RTP, 2000
1,986 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Health, Toxicology and Mutagenesis, Small Animals
View Paper: https://www.semanticscholar.org/paper/5d9dfa842ee30f3a308737d1a422551c94e8c709
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- P. O'Brien
- Zhonggang Hou
- William Irwin
- William L. Murphy
- D. Díaz
- Nicholas E. Propson
- E. Howard-Cofield
- Michael P. Schwartz
Citations in the corpus
- Human pluripotent stem cell-derived neural constructs for predicting neural toxicity (2015, background): “Success rates for drug approval are declining despite higher research and development spending (6), and clinical trials often fail due to toxicities that were not identified through animal testing (7).”
- High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening (2006, background): “Along with hypersensitivity and cutaneous reactions, hepatotoxicity has the poorest correlation with regulatory animal toxicity tests (Olson et al. 1998, 2000).”
- Biology-inspired Microphysiological System Approaches to Solve the Prediction Dilemma of Substance Testing (2016, neutral): “Leist and Hartung, 2013; Matthews, 2008; Olson et al., 2000; Perel et al., 2007; Hartung and Leist, 2008; Schnerch et al., 2010; Sena et al., 2010; Seok et al., 2013; van der Worp et al., 2010; Hartung, 2013).”
- Idiosyncratic drug hepatotoxicity (2005, background): “This is not to say that animal toxicology studies are worthles”
- Toxicity Testing in the 21st Century Beyond Environmental Chemicals (2015, background): “Many adverse effects are only found in these clinical phases of drug development (Olson et al., 2000; Hartung and Zurlo, 2012; Hartung, 2013).”